LabGenius is a privately held, synthetic biology company based in London, UK. It uses a combination of artificial intelligence, DNA synthesis, and robotics to discover high-value biological molecules.
The company's novel technology is able to produce trillions of variations of gene sequences, which can be used to create new biological materials using artificial intelligence. It can predict which gene mutations will improve a biological design, thereby enabling scientists to produce new therapeutics or other materials such as adhesives, catalysts, and sensors.
LabGenius, in partnership with leading multinationals, is developing various products, focusing on the areas of biotherapeutics, advanced materials, and personal care. In the biotherapeutics category, LabGenius' AI-driven evolution engine, EVA, is learning how to optimally enhance the stability of therapeutic proteins in protease rich environments such as the GI tract, tumor microenvironments, and inflammed tissues. The end goal is to enable the delivery of novel therapies for unmet clinical needs.
In the advanced materials area, engineered proteins can be used to form high value coatings, adhesives, fibres, catalysts, and sensors. LabGenius has completed several development projects in this area and are engaged in collaborative development with aerospace and defence companies.
LabGenius raises a $10,000,000 series A round from Air Street Capital, Obvious Ventures, iNovia Capital, Felicis Ventures, Lux Capital Management and Gigafund.
LabGenius raises $3.66m of investment
Dr. Adam Tomassi-Russel
Chief Commercial Officer
Dr. Annelie Oswald
Dr. Ben Mackrow
Dr. Chris Cozens
Dr. Eyal Kazin
Dr. Fiona Rowan
Dr. Katya Putintseva
Dr. Maria Bagniewska
Dr. Pedro Tizei
Dr. Pierre-Yves Colin
Dr. Richard Menzies-Wilson
Full Stack Developer
Founder & CEO
Head of Non-Dilutive Financing
Documentaries, videos and podcasts
London, England, United Kingdom
Machine learning for protein therapeutics